Meet Dr. Christoph Klade, the newest member of the Rare Disease specialist...
With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan....
View ArticleAndreas Steiner – New CFO at AOP Orphan
The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53), with many years of management...
View ArticleAOP Orphan spins off its stake in Activartis and outlines business strategy
AOP Orphan Pharmaceuticals AG today announced the spin off of its 80 % stake in Activartis GmbH, a Vienna-based biotech company with a strong platform for immune-based cancer vaccines, to a group of...
View ArticleMeet Dr. Christoph Klade, the newest member of the Rare Disease specialist...
With the arrival of Dr. Christoph Klade (43), we are pleased to welcome a renowned expert to our management team. He will be in charge of research and development activities sector here at AOP Orphan....
View ArticleAndreas Steiner – New CFO at AOP Orphan
The Austrian pharmaceutical company AOP Orphan – a European pioneer in the field of rare diseases – has brought on board a health sector expert, Andreas Steiner (53), with many years of management...
View Article
